Try our Advanced Search for more refined results

Health Care Ruling Could Mean Years Of Delay For Biosimilars

By Rachel Slajda (June 14, 2012, 10:17 PM EDT) -- If the U.S. Supreme Court decides to strike down the entire health care law it could delay the debut of biosimilars onto the U.S. market for months or even years — along with their potential to cut billions of dollars from the country's total drug spending — especially if Congress devolves into partisan squabbling over re-enacting the biosimilars provisions. ...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Read the full article

Already a subscriber? Click here to login

Related Sections

Law Firms

Companies

Government Agencies

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!